Chinese Newcomers Look For Niche Immuno-Oncology Opportunities
Cervical Cancer, SCLC Eyed
Chinese pharma companies are continuing to pile into the already overcrowded domestic anti-PD-1/L1 sector in China, but despite the competition and regulatory tightening, the latecomers are looking for opportunities in areas such as cervical and small cell lung cancer with relatively fewer contenders.
